• Kodiak Sciences recently reported 2025 results showing a wider full-year net loss of US$229.97 million and disclosed that its auditor raised going concern doubts, even as the company filed an US$83.15 million shelf registration tied to an ESOP-related share offering.
• In parallel, Kodiak reported past positive Phase 3 GLOW2 data for its Zenkuda biologic in diabetic retinopathy and moved to accelerate a multi-indication Biologics License Application, highlighting a sharp contrast between its advancing clinical pipeline and its pressured financial profile.
• Against this backdrop, we’ll explore how Zenkuda’s Phase 3 success and accelerated BLA plans reshape Kodiak Sciences’ investment narrative.

Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

What Is Kodiak Sciences' Investment Narrative?

To own Kodiak Sciences today, you have to believe Zenkuda’s Phase 3 data can be converted into an approved, commercially relevant retinal drug before the balance sheet bites. The GLOW2 readout and accelerated multi‑indication BLA plans strengthen the near term catalyst stack around Zenkuda and the IL‑6 franchise, and help explain why the stock has run very hard over the past year. At the same time, the 2025 net loss of US$229.97 million, a second straight going concern flag from PwC, and less than a year of cash runway keep financing risk front and center, even after the US$83.15 million ESOP‑related shelf registration. In other words, the science story has improved, but the funding and dilution question has become more pressing, not less.

Kodiak Sciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Simply Wall St Community fair value estimates currently sit at US$0, reflecting one very cautious view. Set against Kodiak’s strong GLOW2 data and fresh going concern warning, this gap underlines how sharply opinions can diverge and why comparing several perspectives on funding risk and clinical execution really matters.

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Kodiak Sciences research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.
• Our free Kodiak Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kodiak Sciences' overall financial health at a glance.

No Opportunity In Kodiak Sciences?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 59 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.